Abstract: The present invention relates to an in vitro method for detecting and/or determining an agent causing cellular damage in a eukaryotic, in particular, mammalian cell, comprising providing a eukaryotic cell that stably expresses an intracellular luciferase enzyme, contacting the cell with an agent suspected to cause cellular damage, and detecting luciferase activity wherein a change of the luciferase activity as detected when compared to a non-damaged genetically modified eukaryotic cell is indicative for an agent causing cellular damage in the eukaryotic cell. The present invention further relates to methods for detecting and/or determining cytoprotection in a eukaryotic cell caused by an agent, methods for screening for an agent causing cellular cytoprotection in a eukaryotic cell, methods for testing the pharmacological safety of an agent based on the method as above, a diagnostic kit and respective uses thereof in the methods of the invention.

Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.

Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.

Abstract: The invention provides a peptide obtainable from C. albicans as well as variants and fragments thereof, and labelled forms of these. The peptide is immunogenic and specific binding partners for the peptide and labelled forms of these specific binding partners form a further aspect of the invention. The peptide is a fragment of the ECE1 protein and has been found to be both immunogenic and act as a pore-forming toxin. A range of therapeutic and diagnostic applications for the peptide and the specific binding partners for it form further aspects of the invention. In addition, the peptide may be used in screens for identifying compounds having useful anti-fungal activity.